cbd medical term urine

Cbd medical term urine

So you’re in the clear, right? Not quite. There are two ways you could hit that 50 ng/mL mark.

While the information here suggests CBD won’t make anyone fail a drug test, there’s no way to guarantee that. The only way to ensure you will pass a drug test is to abstain from using any sort of CBD product.

When it comes to marijuana, drug tests typically only screen for THC — the compound in cannabis that gets you “high” — or one of the compounds created when your body metabolizes it. And by law CBD products can only contain up to 0.3% THC.

Get the CNET Daily News newsletter

Depending on how much CBD (and thus THC), you consume, how often you consume it, your body weight and your diet, it’s possible for THC to accumulate in your body in as little as four to six days and trigger a positive drug test. Research has found that THC can be detectable in your system for up to 30 days, but it’s usually only present in heavy cannabis users after the first week.

To hit 50 ng/mL of THC, you’d probably have to consume upwards of 2,000 mg of CBD products that contain 0.3% or less of THC, which is much higher than the average person is likely to take. Even in clinical trials and research studies, people are usually only administered 100-800mg/day.

Why CBD might cause you to fail a drug test

Second, there’s a good chance that the CBD product you’re using contains more than the .3% THC legally allowed. In fact, when Penn Medicine researchers bought CBD products online and then analyzed their ingredients, they found that about one in five contained up to 6.4 mg/ML of THC — high enough to cause impairment.

alt=”urine drug test” width=”1092″ height=”815″ />Canva

Cbd medical term urine

Other confounding factors for the physician include the diverse forms of marijuana used and the variable potency of the marijuana cannabinoids in the different products. The potency of the psychoactive component of marijuana (THC) has increased over time. The physician’s position in this conundrum is problematic. The physician may not prescribe marijuana since that is illegal. In states where legalized, the physician may provide a recommendation that the patient “qualifies” for medical marijuana therapy. Such a recommendation is only a stipulation that the patient may, in essence, self-prescribe. The patient will select the marijuana used from many offerings, perhaps guided by a dispensary. An assay for CBD is an added resource for physicians to identify a marijuana form that may be medically valuable. Further, CBD, although pharmacologically active, is not psychotropic. Strains of marijuana in which CBD is the major cannabinoid have been named Hippie’s disappointment. Such a strain is also known as Charlotte’s Web, named after a young child with intractable seizures alleviated by CBD. Reports of medical benefit include seizures, multiple sclerosis, neurologic disorders with spasms and neurologic pain, pain associated with cancer, rheumatoid arthritis, fibromyalgia, Crohn’s disease, and other autoimmune disorders. Marijuana provides control of nausea and stimulation of appetite in immunosuppressed patients. Migraine headaches, insomnia, and glaucoma are benefitted by medical marijuana.

Marijuana is classified by the Drug Enforcement Agency (DEA) as Schedule I, drugs having no accepted medical value. Twenty-three states and the District of Columbia have legalized medical marijuana. This conflict inhibits physicians from prescribing marijuana and the systematic study of marijuana in medical care. This study concerns the use of the clinical laboratory as a resource for physicians recommending cannabidiol (CBD) to patients, or for patients using medical marijuana. Marijuana containing delta-9-tetrahydrocannabinol (THC) is psychoactive. CBD is not psychoactive. CBD is reported to have medical benefit for seizure control, neurologic disorders including multiple sclerosis, neuropathic pain and pain associated with cancer. Use of opiates leads to increasing dosage over time that may cause respiratory depression. The Medical Board of California has termed this a serious public health crisis of addiction, overdose, and death. Is it feasible that CBD might alleviate persistent, severe pain and therefore diminished opiate use? Further study is needed to determine medical effectiveness of CBD including the effect on concurrent opiate therapy due to competition for receptor sites. This study is the application of a gas chromatography mass spectrometry procedure adapted for use in our laboratory, to detect CBD in urine. The intended use is as a tool for physicians to assess that marijuana being used by a patient is of a composition likely to be medically effective. A law ensuring physicians freedom from federal prosecution would provide confidence essential to formal study of medical uses of marijuana and treatment of clinical problems. Detection of CBD in a urine sample would be a convenient test for such confirmation.

Legalization has been heterogeneous. 2 The uncertainties of both law and marijuana products inhibit physicians from recommending marijuana for medical care of patients and inhibit the systematic study of the use of marijuana in medical care. 3 The physician’s position is problematic in this conundrum, which has been called a “natural experiment”. 4

A single volunteer was studied to develop a time profile of the detection time of urinary CBD postdose.

Discussion

Notes: Peak urinary level achieved approximately 3 hours postdose. Urine continued to test positive at 24 hours postdose CBD quantitative result corrected for creatinine concentration.

This CBD assay is reliable, and is performed on standard laboratory equipment. The assay is suitable as a convenient test to provide an assessment as to whether CBD is a cannabinoid in marijuana currently being used. Coupled with as assay for urinary carboxy-THC, testing discloses the principle cannabinoids and whether that composition is CBD only, THC only, or a combination of CBD and THC. The physician is provided information that enables a judgment as to the value of marijuana therapy in the patient. Legislative changes, as distinguished from a policy preference by the Department of Justice, that ensured that physicians complying with state laws were not at risk for Federal prosecution would provide confidence; a confidence that is essential to increased formal study of medical uses of marijuana as well as use of medical marijuana as an effective agent for clinical problems.

However, as Leung 5 has depicted by two case scenarios, it is inevitable that marijuana has already entered into the practices of physicians, whether disclosed by patients or not. The number of patients entering into the practices of physicians may increase since it is likely “marijuana use will rise under legalization”. 4

Video abstract

All (40) urine samples in the Group I tested negative for urine CBD. It is likely that this group represented individuals who had used marijuana for recreational purposes. All (40) tested positive for the THC metabolite, carboxy-THC.

The detection method is a GC/MS procedure performed on an Agilent 6890 GC (gas chromatography) coupled with an Agilent 5973 Mass Selective Detector (Agilent Technologies, Santa Clara, CA, USA). The GC is equipped with a Zebron ZB-5 capillary column (5% phenyl–95% dimethylpolysiloxane liquid phase), 15 m, 0.25 mm internal diometer, 0.25 µm film thickness (Agilent Technologies). The GC uses a temperature ramp of 160°C–250°C at 25°C/min held for 1 minute. Quantitation occurs using the internal standard method.